许东旭, 张海锋, 李新立 . 《生物标志物在心衰预防、评估以及管理中的作用》解读[J]. 上海大学学报(自然科学版), 2017 , 23(6) : 821 . DOI: 10.12066/j.issn.1007-2861.1970

[1] Chow S L, Maisel A S, Anand I, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American heart association[J]. Circulation, 2017, 135: 1054-1091.

[2] BIOMARKERS DEFINITIONS WORKING GROUP. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework [J]. Clinical Pharmacology & Therapeutics, 2001, 69(3): 89-95.

[3] Francis G S, Benedict C, Johnstone D E, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. a substudy of the Studies of Left Ventricular Dysfunction (SOLVD) [J]. Circulation, 1990, 82(5): 1724-1729.

[4] Lopez B, Gonzalez A, Querejeta R, et al. The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease [J]. Journal of Hypertension, 2005, 23(8): 1445-1451.

[5] Spinale F G, Zile M R. Integrating the myocardial matrix into heart failure recognition and management [J]. Circulation Research, 2013, 113(6): 725-738.

[6] Hartupee J, Mann D L. Positioning of inflammatory biomarkers in the heart failure landscape[J]. Journal of Cardiovascular Translational Research, 2013, 6(4): 485-492.

[7] Kakkar R, Lee R T. The IL-33/ST2 pathway: therapeutic target and novel biomarker [J]. Nature Reviews Drug Discovery, 2008, 7(10): 827-840.

[8] Liu Y H, D’Ambrosio M, Liao T D, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growthregulatory lectin [J]. American Journal of Physiology Heart & Circulatory Physiology, 2008, 296(2): 404-412.

[9] Sharma U C, Pokharel S, van Brakel T J, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction [J]. Circulation, 2004, 110(19): 3121-3128.

[10] de Boer R A, Voors A A, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression [J]. European Journal of Heart Failure, 2009, 11(9): 811-817.

[11] Yu L, Ruifrok W P, Meissner M, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis [J]. Circulation: Heart

Failure, 2013, 6(1): 107-117.

[12] Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure [J]. Journal of American College of Cardiology, 2006, 47(4): 742-748.

[13] Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload [J]. the Journal Clinical Investigation, 1995, 96(3): 1280-1287.

[14] Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure [J]. Circulation, 1994, 90(1): 195-203.

[15] Tijsen A J, Pinto Y M, Creemers E E. Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases [J]. American Journal of Physiology Heart & Circulatory Physiology, 2012, 303(9): 1085-1095.

[16] Yancy C W, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J]. Journal of the American College of Cardiology, 2013, 62(16): 147-239.

[17] Velagaleti R S, Gona P, Larson M G, et al. A multimarker approach for the prediction of heart failure incidence in the community [J]. Circulation, 2010, 122(17): 1700-1706.

[18] Glick D, de Filippi C R, Christenson R, et al. Long-term trajectory of two unique cardiac biomarkers and subsequent left ventricular structural pathology and risk of incident heart failure in community-dwelling older adults at low baseline risk [J]. JACC: Heart Failure, 2013, 1(4): 353-360.

[19] Brouwers F P, van Gilst W H, Damman K, et al. Clinical risk stratification optimizes value of biomarkers to predict new-onset heart failure in a community-based cohort [J]. Circulation

Heart Failure, 2014, 7(5): 723-731.

[20] Brouwers F P, de Boer R A, van der Harst P, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND [J]. European Heart Journal, 2013, 34(19): 1424-1431.

[21] Mckie P M, Cataliotti A, Sangaralingham S J, et al. Predictive utility of atrial, Nterminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study [J]. Mayo Clinic Proceedings, 2011, 86(12): 1154-1160.

[22] de Filippi C R, de Lemos J A, Christenson R H, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults [J]. JAMA, 2010, 304(22): 2494-2502.

[23] Saunders J T, Nambi V, de Lemos J A, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study [J]. Circulation, 2011, 123(13): 1367-1376.

[24] Daniels L B, Laughlin G A, Clopton P, et al. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study [J]. Journal of American College of Cardiology, 2008, 52(6): 450-459.

[25] Wallace T W, Abdullah S M, Drazner M H, et al. Prevalence and determinants of troponin T elevation in the general population [J]. Circulation, 2006, 113(16): 1958-1965.

[26] Lam C S, Lyass A, Kraigher-Krainer E, et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community [J]. Circulation, 2011, 124(1): 24-30.

[27] Wang T J, Wollert K C, Larson M G, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study [J]. Circulation, 2012, 126(13): 1596-1604.

[28] Hughes M F, Appelbaum S, Havulinna A S, et al. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality [J]. Heart, 2014, 100(21): 1715-1721.

[29] Dadu R T, Dodge R, Nambi V, et al. Ceruloplasmin and heart failure in the atherosclerosis risk in communities study [J]. Circulation Heart Failure, 2013, 6(5): 936-943.

[30] Kalogeropoulos A, Georgiopoulou V, Psaty B M, et al. Inflammatory markers and incident heart failure risk in older adults: the health ABC (health, aging, and body composition) study [J]. Journal of the American College of Cardiology, 2010, 55(19): 2129-2137.

[31] Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients [J]. Circulation, 2004, 110(15):

2168-2174.

[32] Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study [J]. Journal of Cardiac Failure, 2001, 7(1): 21-29.

[33] Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure [J]. Journal of American College of Cardiology, 2004, 43(4): 635-641.

[34] del Carlo C H, Pereira-Barretto A C, Cassaro-Strunz C, et al. Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure [J]. Journal of Cardiac Failure, 2004, 10(1): 43-48.

[35] Metra M, Nodari S, Parrinello G, et al. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T[J]. European Journal of Heart Failure, 2007, 9(8): 776-786.

[36] Metra M, Cotter G, Davison B A, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes[J]. Journal of the American College of Cardiology, 2013, 61(2): 196-206.

[37] Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure [J]. Journal of Cardiac Failure, 2008, 14(9): 732-738.

[38] Breidthardt T, Balmelli C, Twerenbold R, et al. Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance [J]. Journal of Cardiac Failure, 2013, 19(12): 821-828.

[39] Butler J, Forman D E, Abraham W T, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients [J]. American Heart Journal, 2004, 147(2): 331-338.

[40] Metra M, Davison B, Bettari L, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function [J]. Circulation: Heart Failure, 2012, 5(1): 54-62.

[41] Greene S J, Gheorghiade M, Vaduganathan M, et al. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial [J]. European Journal of Heart Failure, 2013, 15(12): 1401-1411.

[42] Testani J M, Chen J, Mc Cauley B D, et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival [J]. Circulation, 2010, 122(3): 265-272.

[43] Felker G M, Lee K L, Bull D A, et al. Diuretic strategies in patients with acute decompensated heart failure [J]. New England Journal of Medicine, 2011, 364(9): 797-805.

[44] Tang W H, Dupont M, Hernandez A F, et al. Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial [J]. JACC: Heart Failure, 2015, 3(1): 40-49.

[45] Chow S L, O’Barr S A, Peng J, et al. Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure [J]. Journal of Cardiac Failure, 2011, 17(3): 181-187.

[46] Bellomo R, Kellum J A, Ronco C. Acute kidney injury [J]. Lancet, 2012, 380(9843): 756-766.

[47] Cruz D N, Soni S, Slavin L, et al. Biomarkers of cardiac and kidney dysfunction in cardiorenal syndromes [J]. Contributions to Nephrology, 2010, 165: 83-92.

[48] Kociol R D, Horton J R, Fonarow G C, et al. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF) linked to medicare claims [J]. Circulation Heart Failure, 2011, 4(5): 628-636.

[49] O’Connor C M, Hasselblad V, Mehta R H, et al. Triage after hospitalization with advanced heart failure: the ESCAPE (evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness) risk model and discharge score [J]. Journal of the American College of Cardiology, 2010, 55(9): 872-878.